Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases

CAMBRIDGE, Mass., and SOUTH SAN FRANCISCO, Calif., Feb. 1, 2022 (GLOBE NEWSWIRE)– Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxyTM polymer nanoparticle platform for tissue-selective delivery, today announced a research collaboration and option agreement under which the companies […] The post Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases first app